BreatheEasy RX: Multi-Pathway Nasal Defense & Seasonal Comfort Model | immunizeLABS
BreatheEasy RX Multi-Pathway Nasal Defense & Seasonal Comfort Compendium
Twelve Active Ingredients Across Four Functional Layers – Cleanse, Hydrate & Protect, Soothe & Open, and Modulate the Allergen Response
Scientific Overview
Most nasal sprays do exactly one thing. Saline rinses. Decongestants constrict blood vessels. Steroids suppress inflammation. Each addresses a single variable in a nasal environment that is, in reality, governed by several at once: the microbial load on the mucosal surface, the hydration and integrity of the epithelial barrier, the inflammatory tone of the tissue, and the perception of airflow that determines whether a person actually feels like they can breathe.
BreatheEasy is built on the premise that these variables are interdependent. A dry, disrupted epithelial barrier clears pathogens poorly. A mucosa under inflammatory load feels blocked even when airflow is adequate. A vasoconstrictor can open the airway while progressively damaging the tissue that keeps it open – the mechanism behind rebound congestion (rhinitis medicamentosa).
The formulation therefore uses eleven active ingredients organized into three functional layers that act on the surface in sequence: a cleansing and neutralizing layer, a hydrating and barrier-protective layer, and a soothing and airflow-sensory layer. Crucially, it contains no vasoconstrictor, no steroid, and no drug – the airway is not forced open; the conditions that close it are addressed.
How to read this document
Every mechanism below is tied to peer-reviewed literature and labeled with its evidence class. Where the evidence comes from a related compound or delivery format rather than this exact formulation, that is stated explicitly. Company-generated performance data is separated from published literature and labeled as such. See Limitations & Disclosures.
Mechanism of Action: Four Functional Layers
Layer 1 – Cleanse & Neutralize (Surface Microbial Load)
Monolaurin · Tri-iodide · Hydroxypropyl-β-Cyclodextrin
- ✓ Monolaurin (glycerol monolaurate) is an amphipathic lipid that partitions into microbial membranes and destabilizes them. Its antibacterial activity is documented in both planktonic and biofilm culture, and it has demonstrated protective effect at a mucosal surface in primate models. PRECLINICAL
- ✓ Iodine (as tri-iodide) is a broad-spectrum oxidizing antiseptic. The clinical literature for nasal iodine antisepsis is established for povidone-iodine formulations, which rapidly inactivate enveloped viruses on nasal surfaces in vitro and reduce nasopharyngeal viral load in randomized trials. RCT
- ✓ Hydroxypropyl-β-cyclodextrin is a cyclic sugar that sequesters membrane lipids – notably cholesterol. Cholesterol depletion by β-cyclodextrins permeabilizes and inactivates enveloped virions and disrupts the lipid-raft microdomains those viruses depend on for entry. It also acts as a solubilizer, carrying poorly water-soluble actives into an aqueous spray. PRECLINICAL
Two independent routes of attack on the same target. Monolaurin inserts into the lipid membrane; hydroxypropyl-β-cyclodextrin extracts cholesterol out of it. Neither depends on the other working.
Mechanism model. Preclinical / in-vitro evidence (PMID 22808139, 19262509, 12857892, 13678470).Layer 2 – Hydrate & Protect (Barrier and Clearance)
Sodium Hyaluronate · Glycerin · D-Panthenol · Sodium Chloride · Sodium Citrate
- ✓ Sodium hyaluronate is a mucoadhesive humectant that binds water at the epithelial surface. In randomized controlled trials it produced faster mucociliary clearance than saline alone – the cilia move mucus, and trapped particles, out more efficiently. RCT
- ✓ D-Panthenol (pro-vitamin B5) converts to pantothenic acid in tissue and supports epithelial proliferation and repair. Randomized, double-blind data show improved mucociliary clearance and symptom relief versus saline in post-surgical nasal care, and it relieves the dry, crusted mucosa of rhinitis sicca. RCT
- ✓ Sodium chloride provides the saline base. Saline irrigation is one of the best-evidenced interventions in nasal care, supported by Cochrane review and meta-analysis for symptom relief and mucociliary function. RCT
- ✓ Glycerin is a humectant that slows evaporative water loss, extending the residence time of the hydrating film rather than draining away in minutes.
- ✓ Sodium citrate buffers the solution to a near-physiologic nasal pH range, avoiding the ciliary irritation associated with poorly buffered sprays.
Layer 3 – Soothe & Open (Inflammatory Tone and Airflow Perception)
Alpha-Bisabolol (Liposomal) · Peppermint Oil · Menthol Lactate
- ✓ Alpha-bisabolol, the principal soothing sesquiterpene of chamomile, suppresses nitric oxide and PGE₂ production and downregulates NF-κB and AP-1 signalling in inflammatory models – lowering inflammatory tone rather than blocking a single mediator. Liposomal encapsulation carries this lipophilic molecule into an aqueous formulation and prolongs surface contact. PRECLINICAL
- ✓ Menthol lactate and peppermint oil act on TRPM8, the cold-sensing receptor abundantly expressed in human nasal mucosa. This layer is the most commonly misrepresented in this category, so we state it precisely: menthol does not decongest. Controlled studies show it does not measurably reduce nasal resistance – it changes the perception of airflow by activating cold receptors, and perceived patency tracks mucosal cooling. That is a feature, not a shortcoming: the sensation of open breathing is delivered without a vasoconstrictor, which is exactly why the formula carries no rebound risk. RCT
Stated plainly: menthol does not decongest. Controlled human studies show no significant change in objective nasal resistance, but a significant increase in the sensation of airflow via TRPM8 cold receptors.
Published human data – PMID 6886530, PMID 1981905. Direction of measured effect.Layer 4: Modulating the Allergen Response
BreatheEasy RX carries every active in BreatheEasy and adds one more: rosmarinic acid, a polyphenol from perilla leaf (Perilla frutescens). This is the entire difference between the two formulas, and it exists for one reason – seasonal allergen exposure.
What it is, stated precisely
Rosmarinic acid is not an antihistamine. It does not block the histamine receptor, and BreatheEasy RX is not a drug. What the published human trial measured was different and, for a daily-use spray, arguably more useful: fewer inflammatory cells arriving in the nasal passage in the first place.
In a 21-day randomized, double-blind, placebo-controlled trial in mild seasonal allergic rhinoconjunctivitis (Takano and colleagues, 2004), perilla extract enriched for rosmarinic acid produced a significant increase in responder rates for itchy nose, itchy eyes, watery eyes, and total symptoms versus placebo. It also significantly reduced neutrophils and eosinophils in nasal lavage fluid – the actual inflammatory cells that drive the itch, the watering, and the congestion. No adverse events were reported.
What the trial actually found. Every endpoint above reached statistical significance versus placebo. The trial reports which endpoints beat placebo rather than publishing effect sizes, so no magnitudes are drawn – a significance map, not a bar chart of invented numbers.
Published RCT – PMID 14988517 (Takano 2004, 21 days, randomized, double-blind, placebo-controlled). Dosing in that trial was oral. See Limitations.Where it acts
The allergic cascade runs in a sequence: allergen lands on the mucosa, immune cells release inflammatory mediators, inflammatory cells infiltrate the tissue, and only then do you feel it. An antihistamine intervenes at the receptor, after the mediator is already released. Rosmarinic acid acts earlier in that chain – damping the inflammatory-cell influx itself.
Upstream of the receptor, not at it. This is why the compendium does not use the word antihistamine. The mechanism is different, the evidence is different, and overstating it would be a drug claim on a drug-free product.
Mechanism model built on the measured outcomes of PMID 14988517, 15630183, and 21239739 – not a claim to treat, cure, or prevent allergic disease.Why this pairs with the other three layers
Allergy season does not only make you itch. It dries the mucosa, degrades the barrier, and leaves the passage inflamed and congested. The other three layers were already built for exactly that – hydration, barrier repair, lower inflammatory tone, restored airflow sensation, with no vasoconstrictor and therefore no rebound. Layer 4 addresses the trigger; layers 1 to 3 address what the trigger does to the tissue.
Formulation & Functional Role
Full active list, by function. Concentrations are proprietary and are not disclosed.
| Ingredient | Layer | Functional Role |
|---|---|---|
| Monolaurin | Cleanse | Membrane-active antimicrobial lipid |
| Tri-iodide | Cleanse | Broad-spectrum oxidizing antiseptic |
| Hydroxypropyl-β-cyclodextrin | Cleanse | Membrane-lipid sequestration; solubilizing carrier |
| Sodium hyaluronate | Hydrate & Protect | Mucoadhesive humectant; supports mucociliary clearance |
| D-Panthenol (pro-vitamin B5) | Hydrate & Protect | Epithelial repair and regeneration support |
| Sodium chloride | Hydrate & Protect | Saline base; osmotic support of clearance |
| Glycerin | Hydrate & Protect | Humectant; extends film residence time |
| Sodium citrate | Hydrate & Protect | pH buffering to a near-physiologic range |
| Alpha-bisabolol (liposomal) | Soothe & Open | Lowers inflammatory signalling tone |
| Peppermint oil | Soothe & Open | TRPM8 cold-receptor activation |
| Menthol lactate | Soothe & Open | Airflow sensation without vasoconstriction |
| Purified water | Vehicle | Aqueous base |
Buffered to a near-physiologic nasal pH range. Contains no vasoconstrictor, no corticosteroid, and no antihistamine.
Synergy Highlights
| Synergy Pair / Complex | Mechanistic Interaction | Expected Benefit | Key Reference |
|---|---|---|---|
| Sodium hyaluronate + Sodium chloride | Saline mobilizes and thins surface mucus; hyaluronate binds water at the epithelium and keeps the surface hydrated after the rinse | A cleared airway that does not immediately dry out | PMID 33843502; PMID 27115216 |
| Sodium hyaluronate + Glycerin + D-Panthenol | A humectant film holds moisture while panthenol supports repair of the epithelium underneath it – protect the surface and rebuild it at once | Sustained comfort; recovery of dry, irritated mucosa | PMID 22379743; PMID 9795928 |
| Hydroxypropyl-β-cyclodextrin + Monolaurin | Cyclodextrin solubilizes and delivers lipophilic monolaurin into an aqueous spray; both act on microbial membrane lipids by complementary routes | Broader surface antimicrobial coverage from a water-based spray | PMID 22808139; PMID 12857892 |
| Tri-iodide + Monolaurin | Oxidative antisepsis paired with membrane disruption – two distinct mechanisms rather than one | Reduced reliance on any single antimicrobial pathway | PMID 32940656; PMID 19262509 |
| Alpha-bisabolol + Menthol lactate | Bisabolol lowers the inflammatory tone that causes the blocked feeling; menthol restores the sensation of airflow via TRPM8 – the cause and the perception, addressed together | Feels open immediately; underlying irritation also addressed | PMID 21771629; PMID 6886530 |
| Whole formula: no vasoconstrictor | Because airflow sensation is produced by cold-receptor activation rather than vessel constriction, the tissue is never driven into the constrict–rebound cycle | No rebound congestion by design – the rhinitis medicamentosa mechanism is absent | PMID 1981905; PMID 23775640 |
Evidence: Visualized
The hydration layer has hard human-trial data behind it. In a randomized, controlled, blinded trial, sodium hyaluronate produced significantly faster mucociliary clearance than saline alone – the cilia move mucus and trapped particles out roughly 40% faster.
Published RCT data – PMID 23862400. Mean ± SD. This is evidence for the ingredient, not a trial of this finished product.
Iodine antisepsis acts in seconds, not minutes. An iodine-class nasal antiseptic completely inactivated enveloped virus in vitro within 15 seconds of contact.
Published in-vitro data – PMID 32940656. Iodine-class evidence (povidone-iodine formulation), not a test of this product.
Why there is no rebound. Rebound congestion is a consequence of repeated adrenergic vasoconstriction and receptor downregulation. BreatheEasy never enters that loop, because it contains no vasoconstrictor.
Mechanism model based on the established pharmacology of rhinitis medicamentosa.
Coverage, side by side. Every other category on this chart does one or two of these jobs. None of them does all of them without a drug, a steroid, or a rebound risk.
Mechanistic comparison based on established pharmacology of each class – not a head-to-head clinical trial.
Eleven actives versus two. A two-ingredient spray can hydrate. It cannot simultaneously address microbial load, epithelial repair, inflammatory tone and airflow perception.
Comparator per the publicly stated formulation of a leading xylitol nasal spray. Ingredient count, not a clinical comparison.
An honest evidence map. The hydration and clearance layer carries the strongest human-trial support. The antimicrobial layer rests predominantly on preclinical and in-vitro work, plus randomized data for iodine-class nasal antisepsis. We show you which is which.
Counts of the peer-reviewed references cited in this document, grouped by the layer they support.
Every ingredient, its pathway, and its evidence – in one table. Each PMID links to a real PubMed record in the reference list below.
Excipients are marked with an em-dash: no efficacy claim is made for them.Figure 1: Formulation Architecture
Cleanse · Hydrate · Soothe
Steroids · Drugs
Multi-pathway by construction. Single-mechanism sprays act on one variable. BreatheEasy distributes eleven actives across three surface functions – and produces airflow sensation without a vasoconstrictor, which is what removes the rebound mechanism entirely.
Source: product formulation. Concentrations proprietary and not disclosed.Figure 2: Active-Ingredient Count vs. a Typical Xylitol Spray
Active Ingredients
Active Ingredients
Coverage, not just presence. A two-ingredient spray can hydrate. It cannot simultaneously address surface microbial load, epithelial repair, inflammatory tone, and airflow perception.
Comparator count per the publicly stated formulation of a leading xylitol nasal spray. This is an ingredient-count comparison, not a head-to-head clinical trial.Figure 3: Published Evidence by Layer
hyaluronate · panthenol · saline
monolaurin · iodine · HP-β-CD
bisabolol · menthol / TRPM8
Every layer is anchored in published literature. The hydration and clearance layer carries the strongest human-trial evidence (randomized trials and Cochrane-level review). The antimicrobial layer rests predominantly on in-vitro and preclinical work, plus randomized data for iodine-class nasal antisepsis.
Counts refer to the peer-reviewed references listed in this document, grouped by the layer they support. Evidence class is labeled on every reference.Company-Reported Product Testing
Kept separate from the published literature above, and labeled as such.
The figures below are generated by immunizeLABS from in-house product testing. They are not peer-reviewed, placebo-controlled clinical trials and should not be read as such.
clearer breathing
immediate comfort
comfort duration
Company-reported onset and duration. Reported clearer breathing at about 60 seconds, with hydrating-film comfort reported up to 6 hours.
COMPANY-REPORTED DATA – immunizeLABS in-house testing. Not a peer-reviewed, placebo-controlled trial.Methodology & Standards
Formulation and testing referenced against internationally recognized protocols (ASTM, ISO, CDC). Human tolerability assessed under ISO 10993-10 (irritation and skin sensitization). Full methodology available on request.
COMPANY DATA These are company-reported outcomes. See Limitations & Disclosures.
Safety & Tolerability Profile
No Rebound Mechanism
Rebound congestion (rhinitis medicamentosa) is caused by repeated adrenergic vasoconstriction. BreatheEasy contains no vasoconstrictor – the mechanism that produces rebound is simply not present in the formula.
Drug-Free, Steroid-Free
No corticosteroid, no antihistamine, no decongestant drug. No systemic drug exposure, and no drowsiness by mechanism.
Ciliary Tolerability
Panthenol-containing nasal formulations have been examined specifically for cytotoxic and ciliary-toxic effects in vitro, supporting the safety of panthenol on nasal mucosa (PMID 12673516).
Buffered to the Nose
Citrate buffering holds the spray in a near-physiologic nasal pH range, avoiding the sting and ciliary irritation of poorly buffered solutions.
Who should speak with a clinician first
Because the formulation contains iodine, individuals with thyroid disease, known iodine sensitivity, or who are pregnant or breastfeeding should consult a healthcare professional before use. Discontinue and consult a clinician if irritation persists.
Comparison with Other Nasal Interventions
| Intervention | Primary Mechanism | Hydration / Barrier | Surface Antimicrobial | Rebound Risk | Drug / Steroid |
|---|---|---|---|---|---|
| BreatheEasy | Multi-layer: cleanse, hydrate/repair, soothe + airflow sensation | Yes – hyaluronate, glycerin, panthenol | Yes – monolaurin, iodine, HP-β-CD | None by mechanism | No |
| Saline spray / irrigation | Mechanical rinse; osmotic support of clearance | Partial – hydrates, but drains quickly | Minimal | None | No |
| Decongestant spray (e.g. oxymetazoline) | Adrenergic vasoconstriction | No – tends to dry the mucosa | No | Yes – classic rebound risk | Yes (drug) |
| Corticosteroid spray | Suppresses the inflammatory cascade | No | No | None | Yes (steroid) |
| Xylitol spray | Osmotic / anti-adherence; hydration | Partial | Limited | None | No |
Mechanistic comparison based on the established pharmacology of each intervention class. This table is not a head-to-head clinical trial.
Using BreatheEasy RX Effectively
- ✔Use as often as needed. There is no vasoconstrictor to build tolerance to.
- ✔Spray once per nostril. Do not blow your nose immediately after – let the formulation coat the nasal passages.
- ✔Use before bed. A hydrated, unobstructed nasal airway supports better sleep.
- ✔Let the film work. The hydrating layer is designed for sustained surface residence, not an instant rinse-and-drain.
Peer-Reviewed References
Every reference links to its PubMed record. RCT denotes randomized/controlled human trials, systematic reviews, or meta-analyses. PRECLINICAL denotes in-vitro, mechanistic, or animal work.
- Casale M, et al. Effect of adjunctive sodium hyaluronate versus surfactant nasal irrigation on mucociliary clearance in allergic rhinitis: a single-blind, randomised, controlled study. J Laryngol Otol. PMID 33843502 RCT
- Macchi A, et al. Effect of sodium hyaluronate on mucociliary clearance after functional endoscopic sinus surgery. PMID 23862400 RCT
- Efficacy of sodium hyaluronate in relieving nasal symptoms of children with intermittent allergic rhinitis: a randomized controlled trial. PMID 34529156 RCT
- Kehrl W, et al. A randomized, prospective, double-blind study of the efficacy of dexpanthenol nasal spray on the postoperative treatment of patients with chronic rhinosinusitis after endoscopic sinus surgery. PMID 22379743 RCT
- Kehrl W, Sonnemann U. Dexpanthenol nasal spray as an effective therapeutic principle for treatment of rhinitis sicca anterior. Laryngorhinootologie. PMID 9795928 RCT
- Hofmann T, et al. The protective effect of dexpanthenol in nasal sprays: cytotoxic and ciliary-toxic studies in vitro. Laryngorhinootologie. PMID 12673516 PRECLINICAL
- Chong LY, et al. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev. PMID 27115216 RCT
- Efficacy of nasal irrigation with hypertonic saline on chronic rhinosinusitis: systematic review and meta-analysis. PMID 32534983 RCT
- Effectiveness of hypertonic saline nasal irrigation for alleviating allergic rhinitis in children: a systematic review and meta-analysis. PMID 30634447 RCT
- Schlievert PM, Peterson ML. Glycerol monolaurate antibacterial activity in broth and biofilm cultures. PMID 22808139 PRECLINICAL
- Li Q, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature. PMID 19262509 PRECLINICAL
- Hess DJ, et al. Antibacterial synergy of glycerol monolaurate and aminoglycosides in Staphylococcus aureus biofilms. PMID 25182634 PRECLINICAL
- Kim S, et al. Inhibitory effects of (−)-α-bisabolol on LPS-induced inflammatory response in RAW264.7 macrophages (NO, PGE₂, NF-κB, AP-1). PMID 21771629 PRECLINICAL
- Rocha NF, et al. Anti-nociceptive and anti-inflammatory activities of (−)-α-bisabolol in rodents. PMID 21870032 PRECLINICAL
- Rocha NF, et al. (−)-α-Bisabolol attenuates visceral nociception and inflammation in mice. PMID 20875845 PRECLINICAL
- In vitro efficacy of a povidone-iodine nasal antiseptic for rapid inactivation of SARS-CoV-2. [iodine-class evidence: povidone-iodine formulation] PMID 32940656 PRECLINICAL
- Virucidal effect of povidone iodine on SARS-CoV-2 in nasopharynx: an open-label randomized clinical trial. [iodine-class evidence] PMID 35572740 RCT
- The effect of povidone-iodine nasal spray on nasopharyngeal SARS-CoV-2 viral load: a randomized control trial. [iodine-class evidence] PMID 34724213 RCT
- Graham DR, et al. Cholesterol depletion of HIV-1 and SIV with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol. PMID 12857892 PRECLINICAL
- Campbell SM, et al. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. PMID 13678470 PRECLINICAL
- Eccles R, et al. The effect of menthol on nasal resistance to air flow. J Laryngol Otol. (menthol alters the sensation of airflow; no decongestant action) PMID 6886530 RCT
- Eccles R, et al. Effects of (−)-menthol on nasal resistance to airflow and nasal sensation of airflow in subjects with nasal congestion associated with the common cold. PMID 1981905 RCT
- Keh SM, et al. The menthol and cold sensation receptor TRPM8 in normal human nasal mucosa and rhinitis. PMID 21991571 PRECLINICAL
- Zhao K, et al. Regional peak mucosal cooling predicts the perception of nasal patency. PMID 23775640 RCT
- Takano H, Osakabe N, Sanbongi C, et al. Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. Exp Biol Med (Maywood). 2004;229(3):247-54. PMID 14988517 RCT
- Osakabe N, Yasuda A, Natsume M, Yoshikawa T. Anti-inflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. Biofactors. 2004;21(1-4):127-31. PMID 15630183 PRECLINICAL
- Sanbongi C, Takano H, Osakabe N, et al. Effect of Perilla frutescens var. acuta Kudo and rosmarinic acid on allergic inflammatory reactions. Exp Biol Med. PMID 21239739 PRECLINICAL
Limitations & Disclosures
Study Limitations
- ✔The rosmarinic acid trial dosed by mouth, not by spray. Takano 2004 (PMID 14988517) administered perilla extract orally. BreatheEasy RX delivers rosmarinic acid topically to the nasal mucosa. The trial supports the ingredient; it is not a trial of this delivery route or of this product.
- ✔That trial was small. It enrolled a few dozen participants with mild seasonal allergic rhinoconjunctivitis over 21 days. It is a genuine randomized, double-blind, placebo-controlled result, and it is one small study – not a body of evidence.
- ✔Rosmarinic acid is not an antihistamine and BreatheEasy RX is not a drug. It does not block histamine receptors. Nothing here is a claim to diagnose, treat, cure, or prevent allergic rhinitis or any other disease. If your symptoms are severe or persistent, see a clinician.
- ✔Ingredient-level, not product-level, evidence. The published literature cited here evaluates the individual actives – frequently in other formulations, concentrations, or delivery formats. It does not constitute a clinical trial of this finished product.
- ✔Iodine evidence is drawn from povidone-iodine formulations. Those trials establish the antiseptic behaviour of nasal iodine as a class; they were not conducted with this product.
- ✔The antimicrobial layer rests substantially on in-vitro and preclinical work. Membrane-disruption and cholesterol-depletion findings for monolaurin and cyclodextrin are mechanistic; they are not equivalent to clinical outcome data.
- ✔Menthol is sensory, not decongestant. We state this deliberately: the perceived opening is real, measurable, and receptor-mediated – but it is a change in the sensation of airflow, not a measured reduction in nasal resistance.
- ✔Company-reported figures are not peer-reviewed. The onset, comfort and duration figures above are internal, and were not placebo-controlled or independently replicated.
Conflict of Interest & Funding
This compendium was prepared and funded by immunizeLABS, which manufactures and sells BreatheEasy. The cited peer-reviewed literature is independent and was not funded by immunizeLABS. Company-generated data is labeled as such throughout.
Disclaimer
- ✔Not Evaluated by the FDA: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- ✔Individual Results Vary: Response depends on your nasal environment, condition, and consistency of use.
- ✔Consult Your Doctor: Particularly if you have thyroid disease or iodine sensitivity, are pregnant or breastfeeding, or are treating a child.
© 2026 immunizeLABS. All rights reserved.
Contact: sales@immunizelabs.com